<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02176876</url>
  </required_header>
  <id_info>
    <org_study_id>GS-US-373-1276</org_study_id>
    <secondary_id>2013-005396-41</secondary_id>
    <nct_id>NCT02176876</nct_id>
  </id_info>
  <brief_title>Safety, Tolerability, and Pharmacokinetics of GS-5745 in Subjects With Rheumatoid Arthritis</brief_title>
  <official_title>A Phase 1b, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study Evaluating the Safety, Tolerability, and Pharmacokinetics of GS-5745 in Subjects With Rheumatoid Arthritis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gilead Sciences</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Gilead Sciences</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is to assess the safety, tolerability, and pharmacokinetics (PK) of multiple&#xD;
      infusions of GS-5745 in adults with rheumatoid arthritis (RA). Participants will be&#xD;
      randomized in a 4:1 ratio to receive 1 intravenous (IV) infusion of GS-5745 or placebo every&#xD;
      2 weeks, for a total of 3 IV infusions.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2014</start_date>
  <completion_date type="Actual">June 2015</completion_date>
  <primary_completion_date type="Actual">April 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of adverse events, changes in laboratory tests and vital signs from baseline, and development of immunogenicity after dosing</measure>
    <time_frame>Up to 100 days</time_frame>
    <description>This composite endpoint will measure the safety and tolerability profile of GS-5745.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>PK profile of GS-5745</measure>
    <time_frame>Pre-infusion, 30 minutes, 4 hours, and 24 hours post-infusion on Day 1; pre-infusion and 30 minutes post-infusion on Days 15 and 29; Days 4, 8, 36, and 43</time_frame>
    <description>This composite endpoint will measure the plasma PK profile of GS-5745. The following parameters will be measured, where applicable:&#xD;
Cmax: maximum observed concentration of drug in plasma&#xD;
Tmax: time of Cmax&#xD;
Clast: last observable concentration of drug&#xD;
Tlast: time of Clast&#xD;
AUClast: concentration of drug from time zero to the last quantifiable concentration&#xD;
AUCinf: concentration of drug extrapolated to infinite time (area under the plasma concentration versus time curve extrapolated to infinite time)&#xD;
AUCtau: concentration of drug over time (area under the plasma concentration versus time curve over the dosing interval)&#xD;
Ctau: observed drug concentration at the end of the dosing interval&#xD;
λz: terminal elimination rate constant&#xD;
CL: systemic clearance of the drug following intravenous administration&#xD;
Vz: volume of distribution of the drug following intravenous administration</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">18</enrollment>
  <condition>Rheumatoid Arthritis</condition>
  <arm_group>
    <arm_group_label>GS-5745</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive GS-5745 every 2 weeks for a total of 3 infusions.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo to match GS-5745</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants will receive placebo to match GS-5745 every 2 weeks for a total of 3 infusions.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GS-5745</intervention_name>
    <description>GS-5745 400 mg administered intravenously</description>
    <arm_group_label>GS-5745</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo to match GS-5745</intervention_name>
    <description>Placebo to match GS-5745 administered intravenously</description>
    <arm_group_label>Placebo to match GS-5745</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  18 to 70 years of age, inclusive, at time of screening&#xD;
&#xD;
          -  Weight: ≥ 45 to &lt; 120 kg&#xD;
&#xD;
          -  Males or non-pregnant, non-lactating females&#xD;
&#xD;
          -  Diagnosis of RA according to the 1987 revised American College of Rheumatology (ACR)&#xD;
             for the classification of RA&#xD;
&#xD;
          -  Active disease, defined as a mean high sensitivity C-reactive protein (hsCRP) value&#xD;
             from Visits 1 &amp; 2 of ≥ 8 mg/L&#xD;
&#xD;
          -  Individuals taking chronic Disease-Modifying Antirheumatic Drugs (DMARDs) should be on&#xD;
             a stable dose for at least 45 days prior to randomization&#xD;
&#xD;
          -  Chronic use of systemic corticosteroids up to a maximum of 10 mg/day of prednisone or&#xD;
             equivalent is allowed if dose is stable for at least 30 days prior to randomization&#xD;
&#xD;
          -  Nonsteroidal Anti-inflammatory Drugs (NSAIDs) or other analgesics are allowed if doses&#xD;
             are stable for at least 30 days prior to randomization&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Have a document medical history of anaphylaxis&#xD;
&#xD;
          -  Positive HIV antibody during screening&#xD;
&#xD;
          -  Positive hepatitis B surface antigen (HBsAg), or positive hepatitis B core antigen&#xD;
             (HBcAg), followed by a positive hepatitis B virus (HBV) DNA by quantitative polymerase&#xD;
             chain reaction (PCR) during screening&#xD;
&#xD;
          -  Positive hepatitis C virus (HCV) antibody followed by a positive HCV viral RNA during&#xD;
             screening&#xD;
&#xD;
          -  A positive QuantiFERON-tuberculosis (TB) GOLD test during screening&#xD;
&#xD;
          -  History of malignancy within the last 5 years except for individuals who have been&#xD;
             treated locally for non-melanoma skin cancer or cervical carcinoma in situ&#xD;
&#xD;
          -  Severe dementia or Alzheimer's disease, chronic medical or psychiatric problem, or&#xD;
             alcohol or drug abuse, that in the judgment of the investigator may interfere with&#xD;
             individual's ability to comply with study procedures&#xD;
&#xD;
          -  Any serious cardiac event such as myocardial infarction, unstable or life-threatening&#xD;
             arrhythmia, hospitalization for cardiac failure within 6 months prior to randomization&#xD;
             or any significant or new ECG finding at Visit 1 as judged by the investigator&#xD;
&#xD;
          -  History of significant systemic involvement secondary to RA such as vasculitis,&#xD;
             pulmonary fibrosis, or Felty's syndrome&#xD;
&#xD;
          -  History of or current inflammatory joint disease, other than RA, such as gout,&#xD;
             reactive arthritis, psoriatic arthritis, seronegative spondylarthritis, or Lyme&#xD;
             disease&#xD;
&#xD;
          -  History of or current autoimmune or rheumatic disorders, other than RA, such as&#xD;
             systemic lupus erythematosus, inflammatory bowel disease, fibromyalgia, polymyalgia&#xD;
             rheumatic, scleroderma, inflammatory myopathy, mixed connective tissue disease, or&#xD;
             other overlap syndrome&#xD;
&#xD;
          -  Any chronic medical condition (including, but not limited to, cardiac or pulmonary&#xD;
             disease) that, in the judgment of the investigator, would make the individual&#xD;
             unsuitable for the study or would prevent compliance with the study protocol&#xD;
&#xD;
          -  Treatment with antibiotics for a clinical infection or other medical condition within&#xD;
             30 days prior to randomization&#xD;
&#xD;
          -  Treatment with azathioprine or cyclosporine 90 days prior to randomization&#xD;
&#xD;
          -  Treatment with infliximab, golimumab, adalimumab, abatacept, tocilizumab within 90&#xD;
             days; and etanercept or anakinra within 30 days of randomization&#xD;
&#xD;
          -  Treatment with rituximab or any B-cell depleting agent within 12 months of&#xD;
             randomization&#xD;
&#xD;
          -  Treatment with any other marketed or investigational biologic within 5 half-lives of&#xD;
             the molecule or if unknown within 90 days of randomization&#xD;
&#xD;
          -  Administration of any investigational drug or use of any investigational device within&#xD;
             30 days prior to randomization&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David Gossage, MD</last_name>
    <role>Study Director</role>
    <affiliation>Gilead Sciences</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Praha</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Balatonfured</city>
        <state>Veszprem</state>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Budapest</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Debrecen</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Czech Republic</country>
    <country>Hungary</country>
  </location_countries>
  <verification_date>June 2015</verification_date>
  <study_first_submitted>June 25, 2014</study_first_submitted>
  <study_first_submitted_qc>June 25, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 27, 2014</study_first_posted>
  <last_update_submitted>June 25, 2015</last_update_submitted>
  <last_update_submitted_qc>June 25, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 29, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>rheumatoid arthritis</keyword>
  <keyword>RA</keyword>
  <keyword>GS-5745</keyword>
  <keyword>MMP9</keyword>
  <keyword>phase 1</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

